FDA approves new head and neck cancer drug

AI executive summary
The story at a glance, best enjoyed with a coffee ☕
The US Food and Drug Administration (FDA) granted accelerated approval to Johnson & Johnson's Rybrevant Faspro for adults with recurrent or metastatic squamous cell carcinoma of the head and neck that progressed after platinum chemotherapy and immunotherapy. This approval, announced on November 5, 2026, represents the first advance in ten years for patients with this aggressive and potentially fatal disease. According to results from the OrigAMI-4 clinical trial, which included 102 patients, the injectable therapy achieved a 42% tumor response rate, more than double current options, and 56% of responders maintained the response for six months or more. The FDA required confirmatory studies for this indication.
🔔 Sign in to follow this story and get its updates.
In this story you will find
AI analysis
Why it matters
This approval represents hope for patients with recurrent or metastatic squamous cell carcinoma of the head and neck who have exhausted other therapeutic options, offering an alternative with more than double the effectiveness of available treatments.
▸▾ Rate, add sources or report this story
Sign in to rate this story and add sources.
Community annexes
Coverage of this same story by other outlets, contributed by readers and checked automatically.
Ask about this coverage
Get an AI answer grounded in reports from different outlets, with links to the sources.